Growth Metrics

Biogen (BIIB) Equity Ratio (2016 - 2026)

Biogen has reported Equity Ratio over the past 18 years, most recently at 0.63 for Q1 2026.

  • For Q1 2026, Equity Ratio rose 4.45% year-over-year to 0.63; the TTM value through Mar 2026 reached 0.63, up 4.45%, while the annual FY2025 figure was 0.62, 4.06% up from the prior year.
  • Equity Ratio for Q1 2026 was 0.63 at Biogen, up from 0.62 in the prior quarter.
  • Over five years, Equity Ratio peaked at 0.63 in Q1 2026 and troughed at 0.0 in Q3 2025.
  • A 5-year average of 0.53 and a median of 0.57 in 2024 define the central range for Equity Ratio.
  • Biggest five-year swings in Equity Ratio: grew 21.53% in 2023 and later crashed 99.69% in 2025.
  • Year by year, Equity Ratio stood at 0.55 in 2022, then increased by 1.11% to 0.55 in 2023, then increased by 8.1% to 0.6 in 2024, then rose by 4.06% to 0.62 in 2025, then grew by 2.01% to 0.63 in 2026.
  • Business Quant data shows Equity Ratio for BIIB at 0.63 in Q1 2026, 0.62 in Q4 2025, and 0.0 in Q3 2025.